Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
The most recent EPS for Novartis AG is $2.02, not beating expectations of $2.03.
How did Novartis AG NVS's revenue perform in the last quarter?
Novartis AG revenue for the last quarter is $2.02
What is the revenue estimate for Novartis AG?
According to 6 of Wall street analyst, the revenue estimate of Novartis AG range from $14.99B to $12.97B
What's the earning quality score for Novartis AG?
Novartis AG has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Novartis AG report earnings?
Novartis AG next earnings report is expected in 2026-05-05
What are Novartis AG's expected earnings?
Novartis AG expected earnings is $14.02B, according to wall-street analysts.
Did Novartis AG beat earnings expectations?
Novartis AG recent earnings of $13.33B does not beat expectations.